Bluejay Diagnostics, Inc. BJDX
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -83.13%
- 1 year
- -92.08%
5D -0.66 (-27.05%)
- Market cap
- 2.01M
- EPS (ttm)
- 3.24
- Shares out
- 552.85K
- P/E ratio
- 0.56
- Forward P/E
- -11.88
- YTD return
- -83.13%
- 1-year return
- -92.08%
- Volume
- 28.61K
- Avg volume
- 326.14K
- Open
- 1.83
- Previous close
- 1.83
- Day's range
- 1.73 – 1.94
- 52-week range
- 1.73 – 28.00
- Beta
- 0.73
Key statistics
- 50-day average
- 4.46
- 200-day average
- 96.26
- Enterprise value
- -7.04M
- Price / book
- 0.20
- Free cash flow
- -5.49M
- Total cash
- 8.06M
- Total debt
- 442.13K
- Return on equity
- -125.25%
- Short % of float
- 0.97%
Fundamental scorecard
4 of 25 checks passed on BJDX’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -8.00 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -256.00 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -272.00 | -712.00 | -440.00 | -161.76% |
| Nov 9, 2023 | Sep 1, 2023 | -328.00 | -832.00 | -504.00 | -153.66% |
| Aug 14, 2023 | Jun 1, 2023 | -600.00 | -1,100.00 | -500.00 | -83.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 3, 2023 | Dawson James | down | Buy | Neutral |
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bluejaydx.com
News
Bluejay Diagnostics Q3 EPS $(1.72) Up From $(4.04) YoY
12 Health Care Stocks Moving In Tuesday's Pre-Market Session Bluejay Diagnostics Announces 1-For-4 Reverse Stock Split, Effective Nov. 3
Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients
Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Your note
Sign in to keep a note on BJDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHASE DONALD R | Director | Stock Award(Grant) | Jan 31, 2023 | 792,852 |
| DEY INDRANIL | Chief Executive Officer | Purchase | Dec 12, 2023 | 233,093 |
| DEY SVETLANA | Director | Purchase | Dec 12, 2023 | 206,067 |
| FISHER KENNETH R | Chief Financial Officer | Stock Award(Grant) | Jan 31, 2023 | 113,184 |
| GEMIGNANI GARY G | Director | Stock Award(Grant) | Jan 31, 2023 | 27,500 |
| WURTH DOUGLAS CLARK | Director | Stock Award(Grant) | Jan 31, 2023 | 2,313,850 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Anson Funds Management LP | 1.16% | 6,386 | 24.27K | Sep 29, 2024 |
| Sabby Management, LLC | 1.10% | 6,104 | 23.20K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.50% | 2,740 | 10.41K | Sep 29, 2024 |
| CVI Holdings, LLC | 0.24% | 1,323 | 5.03K | Jun 29, 2024 |
| UBS Group AG | 0.22% | 1,229 | 4.67K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.19% | 1,053 | 4.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.07% | 403 | 1.53K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 1 | 3 | Oct 30, 2024 |
